Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.10.0.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Accrued liabilities     $ 7,092
Liabilities associated with discontinued operations, current     $ 7,092
Lymphoseek sales revenue $ 2,917,213  
Cost of goods sold 364,192  
Gross profit 2,553,021  
Operating expenses of discontinued operation:          
Research and development (5,951) 2,453 382,070  
Selling, general and administrative 805,464  
Total operating expenses (5,951) 2,453 1,187,534  
(Loss) income from discontinued operations 5,951 (2,453) 1,365,487  
Interest expense (1,718,506)  
(Loss) income before income taxes 5,951 (2,453) (353,019)  
Benefit from (provision for) income taxes (552) 515 20,181  
(Loss) income from discontinued operations $ 5,399 $ (1,938) $ (332,838)